Navigation Links
Whistleblowers' Complaints Lead Eli Lilly to Pay $800 Million to Settle Civil Medicaid Fraud Charges, According to Berg & Androphy
Date:1/15/2009

HOUSTON, Jan. 15 /PRNewswire/ -- The $800 million settlement that Eli Lilly and Company (NYSE: LLY) has agreed to pay to settle civil False Claims Act charges related to allegedly false or fraudulent marketing, promotion and sale of its drug Zyprexa can be traced to the courageous stands taken by employee whistleblowers, according to the Berg & Androphy law firm.

The company's settlement with the federal government, which also includes a guilty plea in a separate criminal action, covers allegations that occurred between September 1999 and December 2005 related to practices prohibited by the federal Food and Drug Administration (FDA) such as the distribution of "misbranded" drugs.

In March, 2005, a whistleblower represented by Joel M. Androphy and Sarah Frazier, of Berg & Androphy in Houston, filed a qui tam action in the U.S. District Court for the Eastern District of N.Y. ("United States v. Eli Lilly," Case No. CV051471) that was transferred to the Eastern District of Pennsylvania (Case No. CV-06-2909).

The whistleblower represented by Berg & Androphy complained of Lilly's illegal marketing, promotion and sale of Zyprexa to children and in higher- than-recommended dosages to adults. The whistleblower also alleged that as part of the marketing and promotional schemes, Lilly encouraged physicians by means of monetary payments.

Mr. Androphy, who authored the book "Federal False Claims Act and Qui Tam Litigation" (Law Journal Press), said, "Our whistleblower client, who resides in New Jersey, is no longer in the pharmaceutical business, but he is proud of the stand he took in this case. He and the eight other whistleblowers who filed lawsuits deserve credit for exposing the conduct alleged in the settlement agreement."

Of the total settlement, $438 million will go to the federal government, and up to $362 million will go to states except those that are pursuing separate litigation. The states have not yet concluded negotiations, but it is believed that most states will accept a share of the settlement. Multiple relators will receive 18 percent of the settlement amounts. The relators' share of the federal settlement is more than $78 million, and could increase to more than $100 million after the resolution of state claims. Lilly also will be obligated to pay legal fees to the relators' attorneys.

The False Claims Act is a Lincoln-era law that allows private citizens with knowledge of fraud on the government to sue and share in the proceeds of any recovery. The law was enacted to combat widespread procurement fraud in the Civil War, but it fell into disuse in the 1940s. Amendments passed in 1986 made the False Claims Act the government's chief weapon in its war on fraud, and the Justice Department used it in its investigations of clinical laboratories and defense contractors in the mid-1990s. In pharmaceutical cases alone, more than $1 billion has been returned to the federal treasury through False Claims Act lawsuits.

     Attorney Contacts: Joel Androphy and Sarah Frazier, Berg & Androphy,
     Houston, 713.529.5622,http://www.bafirm.com.

     Media Contact: Erin Powers, Powers MediaWorks LLC, for Berg & Androphy,
     281.703.6000.

'/>"/>
SOURCE Berg & Androphy
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MAQUET Cardiovascular Announces Patent Infringement Complaints Against Terumo
2. More marital happiness = less sleep complaints
3. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
4. Robert J. Heine, M.D., Ph.D., F.R.C.P. to Join Lilly; Distinguished Diabetes Expert to Lead Diabetes/Endocrine Medical Division
5. Lauren Marangell, M.D. to Join Lilly; Internationally Recognized Expert in Depression Joins as Distinguished Lilly Scholar
6. Genentech/Roches Lucentis and Eli Lillys Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets
7. Lillys CEO Calls for Reform of Nations Drug Safety System
8. Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels
9. Lilly Grant to VA Will Enhance Services for Returning Combat Veterans
10. Lilly Delivers Strong Third-Quarter Results
11. Lilly and MacroGenics Announce Licensing and Collaboration Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... 24, 2017 , ... Every year, thousands of dedicated Higher Education and K12 ... event is coupled with a dynamic theme like Camp Canvas; this year, they’ve managed ... 0017. , To extend their partnership with Canvas beyond the LMS integration, Modo ...
(Date:7/24/2017)... , ... July 24, 2017 , ... ... media initiatives designed to promote awareness for Topricin’s revolutionary, natural, after-burn skin care ... one of the leading causes of long term skin conditions, including cancer. ...
(Date:7/24/2017)... ... ... although people are taking more steps to protect themselves from sunburn, half of all adults ... within the past year. It’s common and people have been dealing with them since the ... become conscientious of the risks that accompany sunburns. , The team at AloeVera.com , ...
(Date:7/24/2017)... ... July 24, 2017 , ... Anyone who uses scales know they ... would a pharmacist using that same scale to dispense medication. The first example is ... These illustrations show why it is important to have the right balance for the ...
(Date:7/24/2017)... ... July 24, 2017 , ... Sharon Kleyne, host of the nationally ... on VoiceAmerica sponsored by Nature’s Tears® EyeMist® recently talked on the air about an ... China. , The article by Zidor Aldama described the situation in which Chinese children ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... 2017 Zymo Research Corp., also known as ,The Epigenetics Company, ... aging in a precise manner using the myDNAge ™ test. Based ... professor of human genetics and biostatistics at the David Geffen School ... , Zymo Research,s proprietary DNAge ™ technology is used to analyze ... ...
(Date:7/11/2017)... 2017  Sysmex America, Inc., a leading provider ... as well as middleware information systems technology, today ... quality assurance easier and more risk free than ... for the innovation that it delivers to the ... assurance processes to a new level with automated, ...
(Date:7/10/2017)... , July 10, 2017  US medical equipment ... in 2021, according to Medical Equipment & ... by Freedonia Focus Reports. Continued increases in demand for ... aging of the population and supported by gains in ... equipment and supplies. New product introductions will also drive ...
Breaking Medicine Technology: